

BAB VII

DAFTAR PUSTAKA

1. Antimicrobial resistance. World Health Organization [Internet]. 2020 [cited 23 August 2020]. Available from: <https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance>
2. Arrang ST, Cokro F, Sianipar EA. Rational Antibiotic Use by Ordinary People in Jakarta. MITRA: Jurnal Pemberdayaan Masyarakat [Internet].2019[cited 23 August 2020];3(1).Available from: <http://ejournal.atmajaya.ac.id/index.php/mitra/article/view/502>
3. Herawati F, Setiasih, Alhabsyi MM, Gunawan W, Palijama DE, Diah LF, et al. A Patient Caregiver Survey in Indonesia: Knowledge and Perception of Antibiotic Use and Microbial Resistance.J Infect Public Health [Internet].2019[cited 23 August 2020]; S1876-0341(19)30173-X. Available from: <https://pubmed.ncbi.nlm.nih.gov/31164316/>
4. Hamdiyati R, Pinatih KJP, Fatmawati NND. Pola Mikroba Pasien Yang Dirawat di *Intensive Care Unite* (ICU) serta Kepekaannya Terhadap Antibiotik di RSUP Sanglah Denpasar Bali Agustus-Oktober 2013. E-J Medika Udayana [Internet].2016[cited 23 August 2020];5(4). Available from: <https://ojs.unud.ac.id/index.php/eum/article/view/19962>
5. Patil PS, Ashok R. Bacteriological Profile And Antimicrobial Susceptibility Pattern In Intensive Care Unit Of Tertiary Care Hospital, Aurangabad. Int J Clin Biomed Res [Internet]. 2017[cited 23 August 2020].;3(3):26-30.

Available from:

<https://www.sumathipublications.com/index.php/ijcbr/article/view/155>

6. Putra IW, Irwanto I, Dharmawati I, Steyaningtyas A, Puspitasari D, Wahyu AD, et al. Microbial Pattern And Antibiotic Susceptibility In Pediatric Intensive Care Unit Dr. Soetomo Hospital, Surabaya. Indonesian J Tropical Infectious Disease [Internet]. 2019[cited 23 August 2020];7(5). Available from: <https://e-journal.unair.ac.id/IJTID/article/view/5737>
7. Palit PL, Tambajong HF, Kambey BI. Gambaran Pola Kuman Pada Pasien Yang Dirawat di Ruang Rawat Intensif RSUP. Prof. Dr. R. D. Kanadou Manado Periode Juli 2017- Juli 2018. JMR [Internet]. 2018[cited 23 August 2020];1(2). Available from: <https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&cad=rja&uact=8&ved=2ahUKEwj9La20bXsAhVVfisKHc7aB7kQFjAAegQIBBAC&url=https%3A%2F%2Fjournal.unsrat.ac.id%2Findex.php%2Fjmr%2Farticle%2Fview%2F22305&usg=AOvVaw1EG7kFWylzkUqaa68NINrn>
8. Akualing JS, Rejeki IPS. Antibiogram. Indones J Clinical Pathol Med Laboratory[Internet].2016[cited 23 August 2020]; 23(1): 90-95. Available from:<https://indonesianjournalofclinicalpathology.org/index.php/patologi/article/view/1191>
9. Joshi S. Hospital Antibigram: A Necessity. Indian J Med Microbiol 2010[cited 26 September 2020];28:277-80. Available from: <https://pubmed.ncbi.nlm.nih.gov/20966554/>

10. Antibiotic Prescribing and Use in Hospitals and Long-Term care. Center for Disease Control and Prevention. 2020[cited 26 September 2020]. Available from: <https://www.cdc.gov/antibiotic-use/healthcare/>
11. Sizar O, Unakal CG. Gram Positive Bacteria. StatPearls [Internet]. 2020 [cited 26 September 2020]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK470553/>
12. Rice LB. Antimicrobial Resistance in Gram-Positive Bacteria. Am J Infect Control [Internet]. 2006 [cited 26 September 2020]; 34(5):S11-S19. Available from: <https://pubmed.ncbi.nlm.nih.gov/16735146/>
13. Jubeh B, Breijyeh Z, Karaman R. Resistance of Gram-Positive Bacteria to Current Antibacterial Agents and Overcoming Approaches. Molecules [Internet]. 2020[cited 26 September 2020];25(12):2888. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356343/>
14. Oliveira J, Reygaert WC. Gram Negative Bacteria. StatPearls [Internet]. 2020[cited 26 September 2020]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK538213/>
15. Healthcare-Associated Infections Gram Negative Bacteria. Center for Disease Control and Prevention [Internet]. 2011 [cited 26 September 2020]. Available from: <https://www.cdc.gov/hai/organisms/gram-negative-bacteria.html>
16. Khalili H, Soltani R, Safhami S, Khavidaki SD, Alijani B. Antimicrobial Resistance Pattern of Gram-Negative Bacteria of Nosocomial Origin at a Teaching Hospital in the Islamic Republic of Iran. East Mediterr Health J

- [Internet]. 2012 [cited 26 September 2020];18(2):172-177. Available from:
<https://pubmed.ncbi.nlm.nih.gov/22571095/>
17. Fungal Diseases Candidiasis. Center for Disease Control and Prevention [Internet]. 2019[cited 26 September 2020]. Available from:
<https://www.cdc.gov/fungal/diseases/candidiasis/index.html>
18. Hankovszky P, Tarsy D, Oveges N, Molnar Z. Invasive Candida Infections in the ICU: Diagnosis and Therapy. J Crit Care Med (Targu Mures) [Internet]. 2015 [cited 26 September 2020];1(4):129-139. Available from:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953294/>
19. Antibiotic Resistance. World Health Organization [Internet]. 2019 [cited 26 September 2020]. Available from: <https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance>
20. Pandey N, Cascella M. Beta Lactam Antibiotics. StatPearls[Internet]. 2020[cited 26 September 2020]. Available from:
<https://www.ncbi.nlm.nih.gov/books/NBK545311/>
21. Bui T, Preuss CV. Cephalosporins. StatPearls [Internet]. 2020[cited 26 September 2020]. Available from:
<https://www.ncbi.nlm.nih.gov/books/NBK551517/>
22. Marshall WF, Blair JE. The Cephalosporins. Mayo Clin Proc [Internet]. 2011[cited 26 September 2020];74(2):187-195. Available from:
<https://pubmed.ncbi.nlm.nih.gov/10069359/>
23. Das N, Madhavan J, Selvi A, Das D. An Overview of Cephalosporin Antibiotics as Emerging Contaminants: a Serious Environmental Concern.

- 3 Biotech[Internet].2019[cited 26 September 2020];9(6):231. Available from: <https://pubmed.ncbi.nlm.nih.gov/31139546/>
24. Labaste F, Grossac J, Bousnes FW, Conil JM, Ruiz S, Seguin T, et al. Risk Factor for Acquisition of Carbapenem-Resistance during Treatment with Carbapenem in the Intensive Care Unit: a Prospective Study. *Eur J Clin Microbiol Infect Dis* [Internet]. 2019[cited 26 September 2020];38(11):2077-2085. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6800833/>
25. Katzung B. *Basic and Clinical Pharmacology*.14th ed. United States: Mc Graw-Hill Education; 2018.
26. Prokhovora I, Altman RB, Djumagulov M, Shrestha JP. Aminoglycoside Interactions and Impacts on the Eukaryotic Ribosome. *Proc Natl Acad Sci U S A* [Internet]. 2017[cited 26 September 2020];114(51):E10899-E10908. Available from: https://www.researchgate.net/publication/321584673_Aminoglycoside_interactions_and_impacts_on_the_eukaryotic_ribosome
27. Wasserman MR, Pulk A, Zhou Z, Altman RB, Zinder JC, Green KD, et al. Chemically Related 4,5-linked Aminoglycoside Antibiotics Drive Subunit Rotation in Opposite Directions. *Nat Commun* [Internet]. 2015[cited 26 September 2020];6:7896. Available from: <https://pubmed.ncbi.nlm.nih.gov/26224058/>
28. Rudra P, Hess KH, Lappierre P, Ghosh P. High Levels of Intrinsic Tetracycline Resistance in *Mycobacterium abscessus* are Conferred by a

- Tetracycline-Modifying Monooxygenase. *Antimicrob Agents Chemother* [Internet].2018[cited 26 September 2020];62(6):e00119-18. Available from: <https://pubmed.ncbi.nlm.nih.gov/29632012/>
29. Park J, Gasparrini AJ, Reck MR, Symister CT, Elliot JL, Vogel JP, et al. Plasticity, Dynamics, and Inhibition of Emerging Tetracycline Resistance Enzymes. *Nat Chem Biol* [Internet].2017[cited 26 September 2020];23(7):730-736. Available from: <https://pubmed.ncbi.nlm.nih.gov/28481346/>
30. Hansen MP, Scott AM, McCullough A, Thorning S, Aronson JK, Beller EM,et al. Adverse Event in People Taking Macrolide Antibiotics Versus Placebo for any Indication. *Cochrane Database Syst Rev*[Internet].2019[cited 26 September 2020](1):CD011825. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353052/>
31. Al-Sulaiti FK, Nader AM, Saad MO, Shaukat A, Parakadavathu R, ELzubair A,et al. Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial. *Eur J Drug Metab Pharmacokinet*[Internet].2019[cited 26 September 2020];44(5):639-652. Available from: <https://pubmed.ncbi.nlm.nih.gov/30919233/>
32. Blaskovich MAT, Hansford KA, Gong Y, Butler MS, Muldoon C, Huang JX,et al. Protein-inspired Antibiotics Active Vancomycin and Daptomycin Resistant Bacteria. *Nat Commun*[Internet].2018[cited 26 September 2020];9:22. Available from: <https://pubmed.ncbi.nlm.nih.gov/29295973/>

33. Mierzejewska KK, Sadlej J, Trylska J. Molecular Dynamics Simulations Suggest Why the A2058G Mutation in 23S RNA Results in Bacterial Resistance against Clindamycin. *J Mol Model* [Internet].2018[cited 26 September 2020];24(8):191. Available from: <https://link.springer.com/article/10.1007/s00894-018-3689-5>
34. Prats AJG, Scaaf HS, Schaaf HS, Draper HR, Cremades MG, Winckler J, et al. Pharmacokinetics, Optimal Dosing, and Safety of Linezolid in Children with Multidrug-Resistant Tuberculosis: Combined Data from two Prospective Observational Studies. *PLoS Med* [Internet].2019[cited 26 September 2020];16(4):e1002789. Available from: <https://pubmed.ncbi.nlm.nih.gov/31039153/>
35. Naisbitt DJ, Hough SJ, Gill HJ, Pirmohamed M, Kitteringham NR, Park BK. Cellular Disposition of Sulphamethoxazole and its Metabolites: Implication for Hypersensitivity. *Br J Pharmacol*[Internet].2011[cited 26 September 2020];126(6):1393-1407. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1565922/>
36. Reinhart JM, Rose W, Panyard DJ, Newton MA, Leibenstein TK, Yee J, et al. RNA Expression Profiling in Sulfamethoxazole-treat Patients with a Range of in Vitro Lymphocyte Cytotoxicity Phenotypes.*Pharmacol Res Perspect*[Internet].2018[cited 26 September 2020];6(2):e00388. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832900/>
37. Geisinger E, Cuebas GV, Mortmn NJ, Syal S. The Landscape of Phenotypic and Transcriptional Responses to Ciprofloxacin in *Acinetobacter*

- baumannii*: Acquired Resistance Alleles Modulate Drug-Induced SOS Response and Prophage Replication. mBio[Internet].2019[cited 26 September 2020];10(3):e01127-19. Available from: https://www.researchgate.net/publication/333703135_The_Landscape_of_Phenotypic_and_Transcriptional_Responses_to_Ciprofloxacin_in_Acinetobacter_baumannii_Acquired_Resistance_Alleles_Modulate_Drug-Induced_SOS_Response_and_Prophage_Replication
38. Zhu JH, Wang BW, Pan M, Zeng YN, Rego H, Javid B. Rifampicin can Induce Antibiotic Tolerance in Mycobacteria via Paradoxical changes in rpoB Transcription. Nat Commun[Internet].2018[cited 26 September 2020];9:4218. Available from: <https://pubmed.ncbi.nlm.nih.gov/30310059/>
39. Pacholak A, Smutek W, Grzeskowiak AZ, Kaczorek E. Nitrofurantoin-Microbial Degradation and Interactions with Environmental Bacterial Strains. Int J Environ Res Public Health[Internet].2019[cited 26 September 2020];16(9):1526. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6539117/>
40. Diep JK, Sharma R, Grosse EJE, Abboud CS, Rao GG. Evaluation of Activity and Emergence of Resistance of Polymyxin B and ZTI-01 (Fosfomicin for Injection) against KPC-Producing *Klebsiella pneumoniae*. Antimicrob Agents Chemother[Internet].2018[cited 26 September 2020];6(2):e01815-17. Available from: <https://pubmed.ncbi.nlm.nih.gov/29203494/>

41. Mazu TK, Bricker BA, Rozas HF, Ablordeppey SY. The Mechanistic Targets of Antifungal Agents: An Overview. *Mini Rev Med Chem*[Internet].2016[cited 26 September 2020];16(7):555-578. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215921/>
42. Step-by step Approach for Development and Implementation of Hospital Antibiotic Policy and Standard Treatment Guidelines. World Health Organization [Internet]. 2011 [cited 26 September 2020]. Available from: <https://apps.who.int/iris/handle/10665/205912>
43. Kapoor G, Saigal S, Elongavan A. Action and Resistance Mechanisms of Antibiotics: A guide for Clinicians. *J Anaesthesiol Clin Pharmacol*[Internet].2017[cited 26 September 2020];33(3):300-305. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672523/>
44. Comprehensive Antibiogram Toolkit: Phase 2 Antibiogram Specifications. Agency for Healthcare Research and Quality[Internet].2014[cited 20 February 2021]; 14-002-4EF. Available from: <https://www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/nh-aspguide/module2/toolkit2/phase2/abspecs-ph2.pdf>
45. Xiao Z, Wang Q, Zhu F, An Y. Epidemiology, Species Distribution, Antifungal Susceptibility and Mortality Risk Factors of Candidemia among Critically Ill Patients: A Retrospective study from 2011 to 2017 in Teaching Hospital in China. *Antimicrob Resist Infect Control*[Internet].

- 2019[cited 26 February 2021];8:89. Available from:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542075/>
46. Pahwa N, Kumar R, Nirkhivale S, Bandi A. Species Distribution and Drug Susceptibility of *Candida* in Clinical Isolates from a Tertiary Care Center at Indore. *Indian J Med Microbiol*[Internet].2014[cited 26 February 2021];44-8. Available from: <https://pubmed.ncbi.nlm.nih.gov/24399387/>
47. Panizo MM, Reviakina V, Dolande M, Selgard S. *Candida* spp. in vitro Susceptibility Profile to Four Antifungal Agents. Resistance Surveillance Study in Venezuelan Strains. *Med Mycol*[Internet].2009[cited 26 February 2021];47(2):137-43. Available from:
<https://pubmed.ncbi.nlm.nih.gov/18651308/>
48. Ghanshani R, Gupta R, Gupta BS, Kalra S, Khedar RS, Sood S. Epidemiological Study of Prevalence, Determinants, and Outcomes of Infection in Medical ICU at Tertiary Care Hospital in India. *Lung India*[Internet].2015[cited 4 Maret 2021];32(5):441-448. Available from:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4586996/>
49. Dewi RS, Radji M, Andalusia R. Evaluation of Antibiotic Use Among Sepsis Patients in an Intensive Care Unit. *Sulran Qaboos Univ Med J*[Internet].2018[cited 4 Maret 2021];18(3):e367-e373. Available from:
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6307646/>
50. Hermsen ED, Zapapas MK, Maiefski M, Rupp ME, Freifeld AG, Kalil AC. Validation and Comparison of Clinical Prediction Rules for Invasive Candidiasis in Intensive Care Unit Patients: A Matched Case-Control Study.

- Crit Care[Internet].2011[cited 1 April 2021];15:R198. Available from:
<https://ccforum.biomedcentral.com/articles/10.1186/cc10366#citeas>
51. Rafat C, Messika J, Barnaud G, Dufour N, Magdoud F, Pomares TB, et al. Hypervirulent *Klebsiella pneumoniae*, a 5-year Study in a French ICU. J Medical Microbiology[Internet].2018[cited 1 April 2021]; 67(8). Available from:<https://www.microbiologyresearch.org/content/journal/jmm/10.1099/jmm.0.000788?crawler=true>
52. Nirwati H, Sinanjung K, Fahrurissa F, Wijaya F, Napitupulu S, Hati VP, et al. Biofilm Formation and Antibiotic Resistance of *Klebsiella pneumoniae* Isolated from Clinical Samples in Tertiary Care Hospital, Klaten, Indonesia. BMC Proc[Internet].2019[cited 1 April 2021];13(20). Available from:
<https://bmcproc.biomedcentral.com/articles/10.1186/s12919-019-0176-7>
53. Magdalena R, Bachtiar A. Antimicrobial Resistance Control Program on the Rational Use of Antibiotics in Eka Hospital Pekanbaru, Indonesia. Paper presented at The 3rd International Conference on Applied Science and Health[Internet]. 2018[cited 1 April 2021]. Available from:
<https://scholar.ui.ac.id/en/publications/antimicrobial-resistance-control-program-on-the-rational-use-of-a>
54. Chawla R. Epidemiology, Etiology and Diagnosis of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Asian Countries. American Journal of Infection Control[Internet]. 2008[cited 6 April 2021]. Available from:

<https://www.sciencedirect.com/science/article/abs/pii/S019665530700715>

8

